Abstract
Cancer immunotherapy targeting immune checkpoint inhibitors (ICIs) has been shown to be a promising strategy in the treatment of various malignancies. Despite the proven efficacy and tolerability of ICIs based on 113 clinical trials globally, data regarding the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of ICIs in the Chinese population are lacking. As of June 1, 2018, not a single ICI has been approved by the China Food and Drug Administration. Currently, there are 26 ongoing phase I studies actively investigating the safety, antitumor activity, and PK/PD profiles of six multinational corporation (MNC)-developed ICIs and eight domestic-developed ICIs in the Chinese population. Data regarding study designs, treatment interventions, targeted populations, and the current states of these studies were collected and summarized. We outlined 8 phase I studies assessing MNC-developed ICIs and 18 phase I studies assessing domestic-developed ICIs in the Chinese population in this article, in order to provide researchers with a clear picture of the status quo of ICI research and developments in China. Immuno-oncology in China remains at a preliminary stage. Despite the substantial amount of phase I studies of ICIs, early-phase...Continue Reading
References
Sep 9, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Evan J Lipson, Charles G Drake
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Aug 29, 2014·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Fu-Sheng WangHong-Yang Wang
Nov 28, 2014·Nature·Thomas PowlesNicholas J Vogelzang
Apr 22, 2015·The New England Journal of Medicine·Edward B GaronUNKNOWN KEYNOTE-001 Investigators
Jan 13, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David F McDermottThomas Powles
Feb 14, 2016·Cancer Immunology Research·Jeffrey WeberY Ann Chen
Mar 10, 2016·Lancet·Jonathan E RosenbergRobert Dreicer
Oct 11, 2016·The New England Journal of Medicine·Robert L FerrisMaura L Gillison
Oct 14, 2016·The Lancet Oncology·Padmanee SharmaJonathan E Rosenberg
Dec 13, 2016·Lancet·Arjun V BalarUNKNOWN IMvigor210 Study Group
Dec 31, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tomasz M BeerWinald Gerritsen
Jan 12, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Julia A BeaverRichard Pazdur
Feb 10, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Amy BaroneRichard Pazdur
Mar 21, 2017·Acta Pharmacologica Sinica·Jie FuHai-Feng Song
Apr 25, 2017·Lancet·Anthony B El-KhoueiryIgnacio Melero
Jun 14, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Solange PetersEnriqueta Felip
Jul 1, 2017·Nature Reviews. Drug Discovery·Asher Mullard
Jul 25, 2017·The Lancet Oncology·Michael J OvermanThierry André
Oct 11, 2017·Seminars in Cancer Biology·Samantha BuruguTorsten O Nielsen
Nov 1, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G LinC Li
Dec 23, 2017·Nature Reviews. Drug Discovery·Shivaani Kummar
Jan 24, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jing HuangYuchen Jiao
Apr 25, 2018·Cancer Immunology, Immunotherapy : CII·Tong ZhangKang Li
May 15, 2018·British Journal of Cancer·Hongnan MoBinghe Xu